Onderzoeker
Max Schreuer
- Trefwoorden:Geneeskunde
- Disciplines:Humane wetenschappen en de kunsten, Ingenieurswetenschappen en technologie, Natuurwetenschappen
Affiliaties
- Faculteit van de Geneeskunde en Farmacie (Faculteit)
Lid
Vanaf27 jan 2016 → 6 nov 2017 - Observerende Klinische wetenschappen (Departement)
Lid
Vanaf1 jan 2014 → 30 sep 2016 - Immunologie en Microbiologie (Departement)
Lid
Vanaf1 okt 2013 → 31 dec 2013
Publicaties
1 - 10 van 15
- Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy(2018)
Auteurs: Teofila Seremet, Simon Planken, Max Schreuer, Yanina Jansen, Mélanie Delaunoy, Hakim El Housni, Danielle Lienard, Véronique Del Marmol, Pierre Heimann, Bart Neyns
Pagina's: 65-70 - Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF(V600)-mutant melanoma(2017)
Auteurs: Max Schreuer, Yanina Jansen, Simon Planken, Ines Chevolet, Teofila Seremet, Vibeke Krüse, Bart Neyns
Pagina's: 464-472 - Sequential treatment strategies and cell-free tumour DNA monitoring in BRAFv600 mutant metastatic melanoma(2017)
Auteurs: Max Schreuer, Bart Neyns
- Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated with Pembrolizumab(2016)
Auteurs: Jeroen M.K. de Filette, Yanina Jansen, Max Schreuer, Hendrik Everaert, Brigitte Velkeniers-Hoebanckx, Bart Neyns, Bert Bravenboer
Pagina's: 4431-4439 - Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma(2016)
Auteurs: Max Schreuer, Geert Meersseman, Sari Van Den Herrewegen, Yanina Jansen, Teofila Seremet, Ambre Bott, Ines Chevolet, Sofie Wilgenhof, Geert Maertens, Bart Neyns
Pagina's: 157-163 - Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients(2016)
Auteurs: Teofila Seremet, Alexander Koch, Yanina Jansen, Max Schreuer, Sofie Wilgenhof, Veronique Del Marmol, Danielle Lienard, Kris Thielemans, Kelly A Schats, Mark Kockx, et al.
- Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors(2016)
Auteurs: Max Schreuer, Geert Meersseman, Sari Van Den Herrewegen, Yanina Jansen, Ines Chevolet, Ambre Bott, Sofie Wilgenhof, Teofila Seremet, Bart Jacobs, Ronald Buyl, et al.
- Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib(2015)
Auteurs: Yanina Jansen, Peter Janssens, Anne Hoorens, Max Schreuer, Teofila Seremet, Sofie Wilgenhof, Bart Neyns
Pagina's: 550-554 - A randomized controlled phase II clinical trial on autologous monocyte-derived mRNA electroporated dendritic cells for stage III/IV melanoma patients who are disease-free following the local treatment of macrometastases(2015)
Auteurs: Jurgen Corthals, Max Schreuer
Pagina's: S673-S673 - Systemic immune changes associated with adjuvant interferon-α2b-therapy in stage III melanoma patients(2015)
Auteurs: Ines Chevolet, Max Schreuer, Reinhart Speeckaert, Bart Neyns, Isabelle Hoorens, Nanja van Geel, Vibeke Krüse, Benjamin Hennart, Delphine Allorge, Mireille Van Gele, et al.
Pagina's: 357-361